ANGN
NASDAQAngion Biomedica Corp.
Latest news
25 items- INSIDERSEC Form 4 filed by Demuth Peter4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Haqq Christopher4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Piekos Brian4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Connelly Robert4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- SECAngion Biomedica Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
- SECAngion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
- SECAngion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
- SECAngion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
- SECSEC Form D filed by Angion Biomedica Corp.D - Elicio Therapeutics, Inc. (0001601485) (Filer)
- INSIDERSEC Form 4 filed by Wilson Karen J4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Chudnovsky Yekaterina4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Nissenson Allen4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Adams Julian4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Venkatesan Jay4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Ashe Carol Gail4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Ruffolo Robert R4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
- INSIDERChudnovsky Yekaterina bought $7,047,530 worth of shares (1,213,000 units at $5.81) (SEC Form 4)4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
- SECAngion Biomedica Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
- SECSEC Form 10-Q filed by Angion Biomedica Corp.10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)
- SECAngion Biomedica Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
- SECAngion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
- SECAngion Biomedica Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
- SECAngion Biomedica Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
ANGN FAQ
7 questionsWhat does Angion Biomedica Corp. do?
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic...Where does ANGN stock trade?
Angion Biomedica Corp. (ANGN) is listed on NASDAQ.What sector and industry is ANGN in?
Angion Biomedica Corp. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Angion Biomedica Corp. go public?
Angion Biomedica Corp. (ANGN) completed its IPO in 2021.What are analysts saying about ANGN?
Angion Biomedica Corp. has had 3 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $800.00 price target on 2021-12-10. Recent price targets range from $800.00 to $1500.00.What companies are similar to ANGN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare ANGN side-by-side with any of them on Quantisnow.How can I track ANGN on Quantisnow?
Quantisnow aggregates Angion Biomedica Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANGN to receive live email and push alerts on every new disclosure.